De novo peptide design
Engineering the molecules of skin longevity.
Novel, patent-protected peptides that target the root molecular drivers of skin aging — designed, not discovered.
The pipeline
Not one molecule — a pipeline.
Cosmetic actives, drug assets and dual-track candidates, spanning the defined drivers of skin aging — every one a novel, patent-filed asset from the same engine.
The platform is the product
Each new target we point the engine at adds another patent-filed program. The pipeline isn't fixed — it compounds as the platform runs.
The pipeline today · cosmetic · drug · dual-track
The thesis
We treat skin-aging proteins like drug targets — and design the molecules that hit them.
Every program
novel & patent-filed
Three tracks
cosmetic, drug & dual
One reusable engine
The same oncology-grade, structure-based AI — calibrated on intractable cancer targets, now turned on skin. A platform that produces novel, patentable peptides.
The problem
Skin aging is molecular. Most skincare isn't designed for it.
Aging is driven by defined biology — yet the multi-billion-dollar "actives" market still leans on a handful of decades-old molecules. New, mechanism-specific actives are rare because discovery is slow, empirical, and expensive.
Defined drivers of skin aging
- 01Glycation — sugar-damaged, stiffened collagen
- 02Oxidative stress & free-radical damage
- 03Collapse of the skin's own antioxidant defense
- 04Elastin breakdown — loss of firmness
- 05Cellular senescence / inflammaging
Today's actives
Retinoids · Vitamin C · Niacinamide · GHK-Cu copper peptides · Matrixyl · Carnosine — old molecules, broad and indirect.
The opportunity
Treat skin-aging proteins like drug targets and design precise modulators — fast, novel, and ownable.
The platform
An oncology-grade discovery engine.
Every candidate runs a gauntlet of validation — from target to filed IP, end-to-end in silico, before any lab spend. Powered by an orchestrated stack of 50+ computational tools, calibrated against experimental ground truth.
How the engine works →Novel by construction
De novo design yields new, patentable chemical matter — not tweaks of generic actives.
De-risked selection
Consensus scoring and honest gates filter weak designs early — built to reject, not flatter.
Capital-efficient
IP is locked before the lab bill — the cheapest possible way to create defensible value.
Where it was proven
Validated where it's hardest: cancer therapeutics.
The engine was built and calibrated on intractable oncology targets — including RAS isoforms (KRAS / HRAS / NRAS). The methodology is proven on the hardest problems in drug discovery; skin is a more tractable application of the same engine.
Affinity-ranking correlation
Predicted vs. measured binding, on known-answer sets.
Binder-vs-decoy separation
True binders cleanly separated from decoys.
Why it's defensible
Novel, owned, and mechanism-specific.
New chemical matter
Patent-protected molecules the incumbents don't own — distinct from the generic, off-patent actives the market relies on.
10 patents filed
Ten U.S. provisional applications filed across the portfolio — composition-of-matter and methods of use.
A compounding moat
Platform + growing IP portfolio + the calibration know-how behind the gates. Each program extends the asset.
The vision
A new category: skin longevity, designed at the molecular level.
Proprietary science can create a new beauty category. We do it with computational discovery instead of lab-first screening — a pipeline of mechanism-specific, patent-protected actives, ready to license or build into an owned, science-first brand.
Get in touch